The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment.
多囊卵巢症候群 (PCOS) 女性的心血管代謝風險:從病理生理到診斷與治療。
Medicina (Kaunas) 2024-10-26
Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.
多囊卵巢症候群中肥胖相關的心血管代謝併發症:鈉葡萄糖共轉運蛋白-2抑制劑的潛在作用。
Front Endocrinol (Lausanne) 2023-04-12
A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
GLP-1對於多囊卵巢症患者體型、代謝和內分泌參數的系統性回顧。
Womens Health (Lond) 2024-03-08
Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.
多囊卵巢綜合症女性的胰高血糖素分泌:肥胖、胰島素敏感性以及二甲双胍和 GLP-1s 治療的作用。
Biomedicines 2024-03-30
Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics.
多囊卵巢綜合症中的腸道微生物及相關合併症;2型糖尿病、非酒精性脂肪肝病(NAFLD)、心血管疾病(CVD)以及微生物治療的潛力。
Probiotics Antimicrob Proteins 2024-04-22
Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review.
生育年齡多囊卵巢症候群 (PCOS) 患者的可用治療及輔助療法:範疇回顧。
Cureus 2024-10-31
Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.
減重介入對多囊卵巢症候群症狀負擔及生物標記的影響:隨機對照試驗的系統性回顧。
Ann Intern Med 2024-11-04
Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?
透過藥物重定位填補多囊卵巢症候群治療的空白:我們取得了什麼成果,現在的進展如何?
Naunyn Schmiedebergs Arch Pharmacol 2024-11-09